Company’s 36-month beta value is 0.82.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NKTR is 178.15M, and currently, short sellers hold a 1.41% ratio of that floaft. The average trading volume of NKTR on April 08, 2024 was 1.85M shares.
NKTR) stock’s latest price update
Nektar Therapeutics (NASDAQ: NKTR)’s stock price has plunge by 0.00relation to previous closing price of 1.32. Nevertheless, the company has seen a 41.30% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-03 that Nektar (NKTR) reported earnings 30 days ago. What’s next for the stock?
NKTR’s Market Performance
NKTR’s stock has risen by 41.30% in the past week, with a monthly rise of 45.07% and a quarterly rise of 133.63%. The volatility ratio for the week is 16.58% while the volatility levels for the last 30 days are 9.77% for Nektar Therapeutics The simple moving average for the past 20 days is 43.42% for NKTR’s stock, with a 112.68% simple moving average for the past 200 days.
Analysts’ Opinion of NKTR
Jefferies gave a rating of “Hold” to NKTR, setting the target price at $1 in the report published on May 10th of the previous year.
NKTR Trading at 70.79% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.04% of loss for the given period.
Volatility was left at 9.77%, however, over the last 30 days, the volatility rate increased by 16.58%, as shares surge +38.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +161.23% upper at present.
During the last 5 trading sessions, NKTR rose by +41.30%, which changed the moving average for the period of 200-days by +141.05% in comparison to the 20-day moving average, which settled at $0.9386. In addition, Nektar Therapeutics saw 133.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from ROBIN HOWARD W, who sale 20,033 shares at the price of $0.68 back on Feb 20 ’24. After this action, ROBIN HOWARD W now owns 879,889 shares of Nektar Therapeutics, valued at $13,622 using the latest closing price.
Zalevsky Jonathan, the Chief R&D Officer of Nektar Therapeutics, sale 9,014 shares at $0.68 during a trade that took place back on Feb 20 ’24, which means that Zalevsky Jonathan is holding 265,025 shares at $6,130 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -1.81 for the present operating margin
- 0.63 for the gross margin
The net margin for Nektar Therapeutics stands at -3.06. The total capital return value is set at -0.47. Equity return is now at value -110.95, with -49.80 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.5 points at debt to capital in total, while cash flow to debt ratio is standing at -1.46. The debt to equity ratio resting at 1.01. The interest coverage ratio of the stock is -6.44.
Currently, EBITDA for the company is -129.61 million with net debt to EBITDA at -1.77. When we switch over and look at the enterprise to sales, we see a ratio of 5.02. The receivables turnover for the company is 40.02for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.45.
Conclusion
In a nutshell, Nektar Therapeutics (NKTR) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
